Organon and Co (OGN) Actualités

Form 8-K - Current report

Form 8-K - Current report

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to...

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

EFFICACY: In the pivotal studies, ADORING 1 and ADORING 2, up to 46% of patients on VTAMA cream achieved vIGA-AD™ treatment success at Week 8...

Form 8-K - Current report

Form 8-K - Current report

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理

（ビジネスワイヤ） -- シャンハイ・ヘンリウス・バイオテック（2696.HK）とオルガノン（NYSE：OGN）は、米国食品医薬品局（FDA）がPROLIA/XGEVA（デノスマ...

US-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)

Wie Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) mitteilten, hat die US-amerikanische Arzneimittelzulassungsbehörde FDA (Food...

Form 8-K - Current report

Organon Reports Results for the Third Quarter Ended September 30, 2024

Third quarter 2024 revenue of $1.582 billion, up 4% as-reported and up 5% at constant currency Third quarter 2024 diluted earnings per share of...

La FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. (2696.HK) et Organon (NYSE : OGN) annoncent que l'Administration américaine des produits alimentaires et...

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the...